Opleiding tot longarts/medisch specialist

De afdeling longziekten geeft vorm aan de opleiding van de longartsen van morgen. Zij heeft een centrale en academische rol in het begeleiden van alle longartsen-in-opleiding van het cluster Leiden.

Op onze afdeling werken gemiddeld 8 artsen in opleiding tot longarts. Deze opleiding duurt 6 jaar en is tot in de details beschreven in het zogenaamde Opleidingsplan longziekten. De longartsen in opleiding (AIOS) zijn samen met de superviserende stafleden verantwoordelijk voor de patiëntenzorg.

De huidige opleiders zijn:

• Opleider: Dr. M.K. (Maarten) Ninaber
• Plaatsvervangend Opleider: Drs. L.S. (Laurie) Steinbusch 

Opleiding tot arts (coassistent)

De afdeling longziekten participeert voor de studie Geneeskunde in het 1e jaars blok Van Basis tot Homeostase en is blokcoördinator van het 2e jaars blok Vraagstukken Borst & Nier. In de masterfase van de studie Geneeskunde draagt de afdeling longziekten ook bij aan het coschap Beschouwend. Ook de semi-arts stage en wetenschapsstage wordt door ons gefaciliteerd.
Voor meer informatie over onderwijs en stages binnen de afdeling longziekten: onderwijs.long@lumc.nl.

Lung cancer

Our research focus is on targeted therapy for lung cancer patients with rare mutations, and on improving immunotherapy for lung cancer. This includes development and evaluation of new treatments, identification of predictive biomarkers for treatment efficacy and unravelling underlying mechanisms. Our research is performed in close collaboration with other teams in the LUMC (including Medical Oncology, Pathology and Radiology), the Netherlands Cancer Institute and other national groups, and international partners.

Chronic obstructive pulmonary disease (COPD) and alpha1-antitrypsin deficiency (AATD)

COPD and AATD have been a focus of our research for a long time, and research in this area includes clinical, translational and basic research. Patients with AATD may develop emphysema/COPD at a relative early age and treatment options are suboptimal. We participate in a large number of international clinical AATD studies, develop biomarkers for treatment efficacy in AATD, and work closely together with the department of Gastroenterology and Hepatology in view of the liver problems AATD patients encounter. Novel cell-based and other treatments for severe emphysema are being evaluated and analyzed using detailed single cell analyses in collaboration with the Department of Immunology. Furthermore, we are performing basic and translational studies on regenerative approaches to repair and regenerate lung tissue using the advanced cell culture models of the PulmoScience laboratory.

Interstitial lung disease (ILD)

ILD is an umbrella term for a wide spectrum of lung diseases that are characterized by more or less extensive fibrotic changes (scarring) in lung tissue. Our research is especially focused on development of ILD in subsets of patients with systemic sclerosis and rheumatoid arthritis, for whom development of ILD is associated with significant morbidity and mortality. Our ILD research is mostly clinical, focusing on novel treatment, but more basic and translational research is being developed by the PulmoScience laboratory. We have a close collaboration with the research groups of the Department of Rheumatology in this area.

Advanced human lung models

The PulmoScience Lab has a long history of developing and using human lung models that are disease- and patient-specific. This includes not only air-liquid interface models of epithelial cells on inserts, but also organoids and lung-on-chip models. Coculture of airway and alveolar epithelial cells with other cell types (endothelial, fibroblasts and immune cells) is included in the various models. Cells are derived from human lung tissue or differentiated from human induced pluripotent stem cells (hiPSC). Models are used for disease modelling of the three clinical focus areas, regenerative medicine as well as for studying the impact of respiratory infections that have a major impact on these patients.